Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Company Info
Highlights
$78.93M
-$3.68
-$200.00K
-$31.78M
$4.64 - $61.90
$46.22
21.78%
9.65
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Corbus Pharmaceuticals Holdings, Inc. (CRBP) returned -45.34% year-to-date (YTD) and -85.00% over the past 12 months. Over the past 10 years, CRBP returned -25.41% annually, underperforming the S&P 500 benchmark at 10.46%.
CRBP
-45.34%
13.36%
-65.65%
-85.00%
-49.75%
-25.41%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of CRBP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -17.03% | -22.88% | -29.67% | 40.68% | -13.65% | -45.34% | |||||||
| 2024 | 338.58% | 16.65% | 26.99% | -5.61% | 15.55% | 5.72% | 31.43% | 2.88% | -66.28% | -22.64% | 11.65% | -33.78% | 95.36% |
| 2023 | 40.36% | -35.74% | 143.14% | 20.77% | 7.86% | -17.21% | -8.16% | 1.39% | -7.67% | -19.14% | 22.75% | -9.72% | 82.20% |
| 2022 | -28.54% | -21.41% | 53.70% | -36.27% | -10.42% | -16.88% | 0.40% | -20.38% | -18.15% | -21.21% | 49.62% | -43.19% | -82.05% |
| 2021 | 46.40% | 19.13% | -9.63% | -8.63% | 20.56% | -15.67% | -25.14% | -5.84% | -20.93% | -1.96% | -13.65% | -28.70% | -50.74% |
| 2020 | 18.50% | -26.74% | 10.55% | 23.66% | 15.12% | 12.47% | -25.27% | 48.09% | -80.61% | -47.79% | 29.83% | 2.46% | -77.11% |
| 2019 | 29.45% | -8.20% | 0.14% | 2.73% | -1.82% | -1.14% | -13.42% | -13.67% | -5.98% | 6.16% | -9.09% | 16.17% | -6.51% |
| 2018 | 5.63% | -1.33% | -17.57% | -2.46% | 4.20% | -18.55% | -0.00% | 15.84% | 29.06% | -11.79% | 3.60% | -15.36% | -17.75% |
| 2017 | -20.71% | 27.61% | -3.51% | -12.73% | -13.89% | 1.61% | -5.56% | 30.25% | -7.74% | -0.70% | 8.45% | -7.79% | -15.98% |
| 2016 | -14.55% | -4.26% | 34.07% | 23.76% | 45.54% | -8.28% | -7.36% | 47.65% | 66.01% | -17.53% | 35.71% | 11.18% | 412.12% |
| 2015 | -29.77% | 19.05% | 12.40% | 12.10% | 5.08% | -6.95% | -36.69% | -2.05% | -17.80% | 3.82% | 9.20% | -7.30% | -44.82% |
| 2014 | 0.00% | -0.33% | -0.33% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CRBP is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Corbus Pharmaceuticals Holdings, Inc. (CRBP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Corbus Pharmaceuticals Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Corbus Pharmaceuticals Holdings, Inc. was 99.31%, occurring on Mar 10, 2023. The portfolio has not yet recovered.
The current Corbus Pharmaceuticals Holdings, Inc. drawdown is 97.92%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.31% | Mar 21, 2017 | 1504 | Mar 10, 2023 | — | — | — |
| -78.79% | Dec 8, 2014 | 296 | Feb 10, 2016 | 146 | Sep 8, 2016 | 442 |
| -50.97% | Oct 10, 2016 | 19 | Nov 3, 2016 | 92 | Mar 20, 2017 | 111 |
| -34.44% | Nov 14, 2014 | 7 | Nov 24, 2014 | 8 | Dec 5, 2014 | 15 |
| -17.44% | Sep 20, 2016 | 4 | Sep 23, 2016 | 8 | Oct 5, 2016 | 12 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Corbus Pharmaceuticals Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Corbus Pharmaceuticals Holdings, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -29.7%.
Valuation
The Valuation section provides an overview of how Corbus Pharmaceuticals Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CRBP compared to other companies in the Biotechnology industry. CRBP currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CRBP relative to other companies in the Biotechnology industry. Currently, CRBP has a P/S ratio of 163.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRBP in comparison with other companies in the Biotechnology industry. Currently, CRBP has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |